Abstract
The sequence specificity of the anti-tumour drug, cisplatin, was determined in a DNA sequence that contained seven telomeric repeats and a run of ten consecutive guanine bases. Cisplatin preferentially forms DNA adducts at consecutive guanine sequences. Hence these DNA sequences were examined in order to gain an insight into the important human genomic regions that are damaged by cisplatin. A polymerase stop/linear amplification assay was employed with an automated DNA capillary sequencer and laser-induced fluorescence detection to quantitatively determine the DNA sequence specificity of cisplatin in a plasmid clone containing seven telomeric repeats and a sequence of ten consecutive guanine bases. It was found that cisplatin preferentially damaged the ten consecutive guanine sequence although the telomeric DNA sequences were also a major site of cisplatin adduct formation.
Keywords: Capillary electrophoresis, Cisplatin, Consecutive guanines, Linear amplification, Polymerase stop assay, Sequence specificity, Telomeres, electropherogram, densitometry, spectroscopy
Anti-Cancer Agents in Medicinal Chemistry
Title: The Sequence Specificity of the Anti-tumour Drug, Cisplatin, in Telomeric DNA Sequences Compared with Consecutive Guanine DNA Sequences
Volume: 12 Issue: 3
Author(s): Vincent Murray and Niruba Kandasamy
Affiliation:
Keywords: Capillary electrophoresis, Cisplatin, Consecutive guanines, Linear amplification, Polymerase stop assay, Sequence specificity, Telomeres, electropherogram, densitometry, spectroscopy
Abstract: The sequence specificity of the anti-tumour drug, cisplatin, was determined in a DNA sequence that contained seven telomeric repeats and a run of ten consecutive guanine bases. Cisplatin preferentially forms DNA adducts at consecutive guanine sequences. Hence these DNA sequences were examined in order to gain an insight into the important human genomic regions that are damaged by cisplatin. A polymerase stop/linear amplification assay was employed with an automated DNA capillary sequencer and laser-induced fluorescence detection to quantitatively determine the DNA sequence specificity of cisplatin in a plasmid clone containing seven telomeric repeats and a sequence of ten consecutive guanine bases. It was found that cisplatin preferentially damaged the ten consecutive guanine sequence although the telomeric DNA sequences were also a major site of cisplatin adduct formation.
Export Options
About this article
Cite this article as:
Murray Vincent and Kandasamy Niruba, The Sequence Specificity of the Anti-tumour Drug, Cisplatin, in Telomeric DNA Sequences Compared with Consecutive Guanine DNA Sequences, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/187152012800228742
DOI https://dx.doi.org/10.2174/187152012800228742 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery Role of Phase II Drug Metabolizing Enzymes in Cancer Chemoprevention
Current Drug Metabolism Signal Transduction of Steroidogenic Hormones to the Adrenal and Gonadal Mitochondria and the Possibilities for Combating Lipoid Congenital Adrenal Hyperplasia
Current Signal Transduction Therapy Pathogenic Mechanisms and Therapeutic Strategies in Spinobulbar Muscular Atrophy
CNS & Neurological Disorders - Drug Targets Gender Differences in P-Glycoprotein Expression and Function: Effects on Drug Disposition and Outcome
Current Drug Metabolism Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry QSAR and Docking Studies of N-hydroxy Urea Derivatives as Flap Endonuclease-1 Inhibitors
Current Computer-Aided Drug Design Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Current Cancer Drug Targets Erythropoietin in Stroke Therapy: Friend or Foe
Current Medicinal Chemistry Novel Therapeutic Strategies Against Cancer: Marine-derived Drugs May Be the Answer?
Anti-Cancer Agents in Medicinal Chemistry The Battle of the Sexes for Stroke Therapy: Female- Versus Male-Derived Stem Cells
CNS & Neurological Disorders - Drug Targets Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design DNA Repair Inhibitors: The Next Major Step to Improve Cancer Therapy
Current Topics in Medicinal Chemistry Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
Anti-Cancer Agents in Medicinal Chemistry Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Current Pharmaceutical Design An Overview of HDAC Inhibitors and their Synthetic Routes
Current Topics in Medicinal Chemistry Aromatase: The Enzyme and Its Inhibition
Anti-Cancer Agents in Medicinal Chemistry Recent Patent-Based Perspective on Diagnostic and Therapeutic Interventions in Malignant Mesothelioma: Is Drug Repositioning Knocking on the Door?
Recent Patents on Anti-Cancer Drug Discovery The Effects of Weightlessness on the Human Organism and Mammalian Cells
Current Molecular Medicine Strategies of overcoming the physiological barriers for tumor-targeted nano-sized drug delivery systems
Current Pharmaceutical Design